Study With Phage for CF Subjects With Pseudomonas Lung Infection

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)

In brief

The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).

Key facts

Study ID: NCT06998043
Run by: BiomX Ltd
People needed: 63
Starts: 2025-07-02
Expected to finish: 2026-09-01
Last updated by the study team: 2025-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
Avanza Medical Center — Pensacola, Florida, United States (enrolling)
Rutgers, Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States (enrolling)
New York Medical College — Hawthorne, New York, United States (enrolling)
Northwell Health — New York, New York, United States (enrolling)
Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)
University of California San Francisco — San Francisco, California, United States (enrolling)
National Jewish Health — Denver, Colorado, United States (enrolling)
Central Florida Pulmonary Group — Orlando, Florida, United States (enrolling)
Providence Alaska Medical Center — Anchorage, Alaska, United States
University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
Stanford University — Palo Alto, California, United States
Joe DiMaggio Children's Health — Hollywood, Florida, United States
University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.